1. Home
  2. CGEM vs SRDX Comparison

CGEM vs SRDX Comparison

Compare CGEM & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • SRDX
  • Stock Information
  • Founded
  • CGEM 2016
  • SRDX 1979
  • Country
  • CGEM United States
  • SRDX United States
  • Employees
  • CGEM N/A
  • SRDX N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • SRDX Medical/Dental Instruments
  • Sector
  • CGEM Health Care
  • SRDX Health Care
  • Exchange
  • CGEM Nasdaq
  • SRDX Nasdaq
  • Market Cap
  • CGEM 366.3M
  • SRDX 416.3M
  • IPO Year
  • CGEM 2021
  • SRDX 1998
  • Fundamental
  • Price
  • CGEM $5.95
  • SRDX $28.87
  • Analyst Decision
  • CGEM Strong Buy
  • SRDX Buy
  • Analyst Count
  • CGEM 7
  • SRDX 3
  • Target Price
  • CGEM $26.00
  • SRDX $43.00
  • AVG Volume (30 Days)
  • CGEM 789.8K
  • SRDX 137.5K
  • Earning Date
  • CGEM 11-06-2025
  • SRDX 11-05-2025
  • Dividend Yield
  • CGEM N/A
  • SRDX N/A
  • EPS Growth
  • CGEM N/A
  • SRDX N/A
  • EPS
  • CGEM N/A
  • SRDX N/A
  • Revenue
  • CGEM N/A
  • SRDX $120,801,000.00
  • Revenue This Year
  • CGEM N/A
  • SRDX N/A
  • Revenue Next Year
  • CGEM N/A
  • SRDX $3.38
  • P/E Ratio
  • CGEM N/A
  • SRDX N/A
  • Revenue Growth
  • CGEM N/A
  • SRDX N/A
  • 52 Week Low
  • CGEM $5.68
  • SRDX $26.00
  • 52 Week High
  • CGEM $17.98
  • SRDX $40.39
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 39.45
  • SRDX 25.36
  • Support Level
  • CGEM $5.68
  • SRDX $29.54
  • Resistance Level
  • CGEM $6.13
  • SRDX $30.19
  • Average True Range (ATR)
  • CGEM 0.29
  • SRDX 0.74
  • MACD
  • CGEM 0.03
  • SRDX -0.21
  • Stochastic Oscillator
  • CGEM 28.42
  • SRDX 6.26

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About SRDX Surmodics Inc.

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Share on Social Networks: